Depomed (NASDAQ:DEPO) : Wednesdays money flow indicated an uptick to downtick ratio was at 2.1. The total value of inflow transactions on upticks was $0.42 million, whereas, the total value of outflow trades on downticks was $0.2 million. The total money flow was $0.22 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $0.01 million. The total value of the trades done on upticks was $0.01 million. Depomed (NASDAQ:DEPO) was trading with a -0.47% change over previous days close. It fell $0.09 during the day and reached $19.14. The stock was 1.38% compared to the previous weeks close.
In an insider trading activity, Vargas Thadd M, officer (Senior VP, BD) of Depomed Inc, unloaded 15,000 shares at an average price of $20 on May 23, 2016. The total amount of the transaction was worth $300,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 5.12% of Depomed shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -20.94% . Institutional Investors own 98.1% of Depomed shares. During last six month period, the net percent change held by insiders has seen a change of -33.45%.
The company shares have dropped -7.81% from its 1 Year high price. On Jul 21, 2015, the shares registered one year high at $33.74 and the one year low was seen on Mar 24, 2016. The 50-Day Moving Average price is $19.54 and the 200 Day Moving Average price is recorded at $17.00. Depomed (NASDAQ:DEPO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $19.52 and $19.10 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $19.73. The buying momentum continued till the end and the stock did not give up its gains. It closed at $19.42, notching a gain of 0.99% for the day. The total traded volume was 2,166,490 . The stock had closed at $19.23 on the previous day.
Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Companys products include Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks. Zipsor, a liquid filled capsule, is a NSAID for the treatment of mild to moderate acute pain. Lazanda nasal spray is used for the management of break through pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. It also has a portfolio of license agreements based on its Acuform gastroretentive drug delivery technology. The Companys product DM-1992 has completed a Phase II trial for Parkinsons disease.